Completed PHASE4 INTERVENTIONAL 2-arm NCT03316807

Immunogenicity of Hepatitis B Vaccination in HIV-infected Adults (HIV)

Immunogenicity and Persistence of Intramuscular High Dose Recombinant Hepatitis B Vaccine in HIV-infected Adults in China

Sponsor: Centers for Disease Control and Prevention, China

Conditions Hepatitis B Vaccine

Interventions 20 µg dose hepatitis B vaccine 60 µg dose hepatitis B vaccine

Updated 7 times since 2017 Last updated: Dec 27, 2021 Started: Oct 31, 2014 Primary completion: Jul 31, 2015 Completion: Jul 31, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Hepatitis B Vaccine, this trial is completed. The trial is conducted by Centers for Disease Control and Prevention, China and has accumulated 7 data snapshots since 2014. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Apr 2022 — Jul 2024 [monthly]

Completed PHASE4
Feb 2021 — Apr 2022 [monthly]

Completed PHASE4

Status: Unknown Status → Completed
Jan 2021 — Feb 2021 [monthly]

Unknown Status PHASE4

▶ Show 2 earlier versions

Nov 2019 — Jan 2021 [monthly]

Unknown Status PHASE4

Status: Active Not Recruiting → Unknown Status
Nov 2017 — Nov 2019 [monthly]

Active Not Recruiting PHASE4

First recorded

Oct 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Centers for Disease Control and Prevention, China
Suping Wang

Data source: Shanxi Medical University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.